<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619970</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-06-00146</org_study_id>
    <nct_id>NCT00619970</nct_id>
  </id_info>
  <brief_title>Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?</brief_title>
  <acronym>CAP&amp;SIBO</acronym>
  <official_title>Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic abdominal pain (CAP) is an extremely pervasive childhood condition and, like IBS in
      adults, it is one of the functional bowel disorders without a clear framework of
      understanding or an effective treatment. However, new research suggests that small intestinal
      bacterial overgrowth (SIBO) may be the unifying pathophysiology that explains the variety of
      symptoms experienced by patients with IBS. As CAP in children is believed to be a precursor
      to IBS in adults, we hypothesize that children with this disorder have a significantly
      greater prevalence of small intestinal bacterial overgrowth (SIBO) than normal, healthy
      children, and that eradication of bacterial overgrowth with antibiotics will reduce symptoms
      of chronic abdominal pain in children with this condition. To prove this, we will first aim
      to determine the prevalence of SIBO in both healthy children and those with CAP. We will do
      this by performing a lactulose breath hydrogen test, the gold standard for the noninvasive
      measurement of SIBO, on 40 healthy controls and 80 subjects with CAP. We will then assess
      whether eradication of SIBO with antibiotics will reduce symptoms of chronic abdominal pain
      in children with this condition. To do this we will randomize, in a double-blinded fashion,
      the 80 CAP patients to receive a 10-day course of either the antibiotic Rifaximin or a
      placebo. After completion of the treatment we will evaluate all these patients for
      eradication of bacterial overgrowth by repeating a lactulose breath hydrogen test. We will
      also assess for symptom improvement by re-administering questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants at Baseline With SIBO</measure>
    <time_frame>upon enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment</measure>
    <time_frame>baseline (week 0) and at 2 weeks post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Chronic Abdominal Pain</condition>
  <condition>Small Intestinal Bacterial Overgrowth</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children receiving Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2/3 Patients with CAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1/3 patients with CAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lactulose Breath Test</intervention_name>
    <description>Healthy controls will receive one lactulose breath test to assess for SIBO</description>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xifaxan</intervention_name>
    <description>xifaxan 550mg TID x10days</description>
    <arm_group_label>Children receiving Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo TID x 10days</description>
    <arm_group_label>Children receiving Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lactulose Breath Test</intervention_name>
    <description>Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo</description>
    <arm_group_label>Children receiving Rifaximin</arm_group_label>
    <arm_group_label>Children receiving Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be between the ages of 8 and 18

          -  Subjects must be able to swallow pills

          -  Healthy Controls must be siblings, other family members or friends of the CAP subjects
             or children who are undergoing an overnight fast in order to obtain AM labs for
             another purpose other than this study.

          -  Female CAP subjects who are sexually active or who may become sexually active during
             the study will be required to practice an effective method of birth control (e.g.,
             oral contraceptives, contraceptive patch or injection, IUD, double barrier method)
             before entering into the study.

          -  All CAP subjects must meet the Rome II Criteria for Functional Bowel Disorders
             Associated with Abdominal Pain or Discomfort in Children

        Exclusion Criteria:

        Subjects will be excluded if they:

          -  have a history of inflammatory bowel diseases, diabetes, cirrhosis or other liver
             disease, juvenile rheumatoid arthritis, systemic lupus, a history of bowel resection
             (including gastric, small bowel or colon; gallbladder surgery or appendectomy are NOT
             exclusion criteria).

          -  have been treated with antibiotics or probiotics within the past 2 months.

          -  have a history of TB infection or positive Mantoux test performed at screening

          -  have a history of allergy to rifampin or rifaximin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brynie S Collins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>September 27, 2016</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Brynie Collins</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Control</title>
          <description>Healthy controls</description>
        </group>
        <group group_id="P2">
          <title>Children Receiving Rifaximin</title>
          <description>2/3 Patients with CAP</description>
        </group>
        <group group_id="P3">
          <title>Children Receiving Placebo</title>
          <description>1/3 patients with CAP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Control</title>
          <description>Healthy controls</description>
        </group>
        <group group_id="B2">
          <title>Children Receiving Rifaximin</title>
          <description>2/3 Patients with CAP</description>
        </group>
        <group group_id="B3">
          <title>Children Receiving Placebo</title>
          <description>1/3 patients with CAP</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants at Baseline With SIBO</title>
        <time_frame>upon enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Control</title>
            <description>Healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Children Receiving Rifaximin</title>
            <description>2/3 Patients with CAP</description>
          </group>
          <group group_id="O3">
            <title>Children Receiving Placebo</title>
            <description>1/3 patients with CAP</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants at Baseline With SIBO</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment</title>
        <time_frame>baseline (week 0) and at 2 weeks post treatment</time_frame>
        <population>1 patient from the treatment group withdrew from the study. Four additional children, 2 from the treatment group and 2 from the placebo group, did not show up for their follow up breath test</population>
        <group_list>
          <group group_id="O1">
            <title>Children Receiving Rifaximin</title>
            <description>2/3 Patients with CAP</description>
          </group>
          <group group_id="O2">
            <title>Children Receiving Placebo</title>
            <description>1/3 patients with CAP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment</title>
          <population>1 patient from the treatment group withdrew from the study. Four additional children, 2 from the treatment group and 2 from the placebo group, did not show up for their follow up breath test</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Control</title>
          <description>Healthy controls</description>
        </group>
        <group group_id="E2">
          <title>Children Receiving Rifaximin</title>
          <description>2/3 Patients with CAP</description>
        </group>
        <group group_id="E3">
          <title>Children Receiving Placebo</title>
          <description>1/3 patients with CAP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brynie Slome Collins MD</name_or_title>
      <organization>CHLA</organization>
      <phone>323 361 2181</phone>
      <email>bcollins@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

